Protection of mice from Mycobacterium avium infection by recombinant interleukin-12
- 1 June 1995
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 39 (6) , 1369-1371
- https://doi.org/10.1128/aac.39.6.1369
Abstract
Treatment with interleukin-12 (IL-12) significantly reduced the number of viable bacteria in mice infected with Mycobacterium avium. IL-12 itself, however, could not inhibit directly mycobacterial growth in vitro. IL-12 exerts antimycobacterial activity in vivo with a low level of toxicity, possibly by enhancing the host defense against the infection.Keywords
This publication has 20 references indexed in Scilit:
- The role of interleukin 12 in the immune response, disease and therapyImmunology Today, 1994
- Interleukin 12 at the site of disease in tuberculosis.Journal of Clinical Investigation, 1994
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor Enhances the Effects of Antibiotics against Mycobacterium avium Complex Infection in the Beige Mouse ModelThe Journal of Infectious Diseases, 1994
- Progress in TB research: Robert Koch's dilemma revisitedImmunology Today, 1994
- IL-12: Initiation Cytokine for Cell-Mediated ImmunityScience, 1993
- Immunity to Intracellular BacteriaAnnual Review of Immunology, 1993
- Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosisImmunology Today, 1991
- Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteriaClinical and Experimental Immunology, 1991
- The role monokines in granuloma formation in mice: The ability of interleukin 1 and tumor necrosis factor-α to induce lung granulomasClinical Immunology and Immunopathology, 1989
- Immune Responses to Atypical Mycobacterial Lung InfectionsClinical Infectious Diseases, 1981